Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?-Reference-Cited by-同舟云学术

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Published:2019-04-29 Issue:6 Volume:24 Page:725-727
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gao Xin¹,McDermott David F.²,Michaelson M. Dror¹

Affiliation:

1. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

2. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Abstract

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2019-0165

Reference29 articles.

1. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma;McKay;J Clin Oncol,2018

2. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges;Fukumura;Nat Rev Clin Oncol,2018

3. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer;Yang;N Engl J Med,2003

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

5. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial;Rini;Lancet,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A rapid review of patient-reported outcomes investigated in the context of advanced renal cell cancer or advanced hepatocellular cancer;European Journal of Oncology Nursing;2023-04

2. The Chromosomes and the Kidney;Physician Assistant Clinics;2022-04

3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities;Frontiers in Immunology;2020-11-05

4. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results;Journal of Translational Medicine;2019-08-29